Nymox Pharmaceutical Corporation will sponsor the Third Manhattan Alzheimer Disease Conference in New York on November 28, 2001. It was rescheduled after the September 11 disaster at the World Trade Center.

As at the earlier Manhattan Conferences, the 2001 Conference will have significant new research advances made public for the first time. The Conference will have a special focus on the medical, social and ethical ramifications of the new emerging diagnostics, in particular in the area of Alzheimer's disease.

Nymox's research and development programs have a specific focus on the diagnosis and treatment of Alzheimers' disease. Nymox is currently offering AlzheimAlert, a state of the art patented urine test designed to aid physicians in the diagnosis of Alzheimer's disease. Nymox is in the early stages of offering the tests to physicians throughout the U.S. Nymox has several major proprietary drug development programs with candidate drugs for Alzheimer's disease, antibiotics and other indications. Nymox Pharmaceutical Corporation has facilities in Montreal and Maywood, NJ. More information is available at www.nymox.com.